Injury, dysbiosis, and filaggrin deficiency drive skin inflammation through keratinocyte IL-1? release - 04/04/19
Abstract |
Background |
Atopic dermatitis (AD) is associated with epidermal barrier defects, dysbiosis, and skin injury caused by scratching. In particular, the barrier-defective epidermis in patients with AD with loss-of-function filaggrin mutations has increased IL-1α and IL-1β levels, but the mechanisms by which IL-1α, IL-1β, or both are induced and whether they contribute to the aberrant skin inflammation in patients with AD is unknown.
Objective |
We sought to determine the mechanisms through which skin injury, dysbiosis, and increased epidermal IL-1α and IL-1β levels contribute to development of skin inflammation in a mouse model of injury-induced skin inflammation in filaggrin-deficient mice without the matted mutation (ft/ft mice).
Methods |
Skin injury of wild-type, ft/ft, and myeloid differentiation primary response gene–88–deficient ft/ft mice was performed, and ensuing skin inflammation was evaluated by using digital photography, histologic analysis, and flow cytometry. IL-1α and IL-1β protein expression was measured by means of ELISA and visualized by using immunofluorescence and immunoelectron microscopy. Composition of the skin microbiome was determined by using 16S rDNA sequencing.
Results |
Skin injury of ft/ft mice induced chronic skin inflammation involving dysbiosis-driven intracellular IL-1α release from keratinocytes. IL-1α was necessary and sufficient for skin inflammation in vivo and secreted from keratinocytes by various stimuli in vitro. Topical antibiotics or cohousing of ft/ft mice with unaffected wild-type mice to alter or intermix skin microbiota, respectively, resolved the skin inflammation and restored keratinocyte intracellular IL-1α localization.
Conclusions |
Taken together, skin injury, dysbiosis, and filaggrin deficiency triggered keratinocyte intracellular IL-1α release that was sufficient to drive chronic skin inflammation, which has implications for AD pathogenesis and potential therapeutic targets.
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Key words : Skin, atopic dermatitis, keratinocytes, filaggrin, IL-1α, inflammation
Abbreviations used : AD, APC, DAPI, FLG, ft/ft mice, IL-1R, IL-1Ra, immuno-EM, MyD88, OTU, PE, PMN, TBS, WT
Plan
Supported by the National Institutes of Arthritis and Musculoskeletal and Skin Diseases (grant no. R01AR069502; to L.S.M., grant no. R01AR073665; to L.S.M., and grant no. K01AR073924; to N.K.A.), the National Institute of Allergy and Infectious Diseases (grant no. R21AI126896; to L.S.M.), and a contract/grant from the Atopic Dermatitis Research Network (U19AI117673-01; to R.S.G. and L.S.M.), and the Division of Intramural Research (ZIAHG000180-17 and ZIABC011558-04; to H.H.K. and J.A.S.) from the US National Institutes of Health, Department of Health and Human Services. Supported also by the Food Allergy Research & Education (FARE), Inc (to M.K.O.), the HOPE APFED/ARTrust TM Pilot Grant (to M.K.O.), the William F. Milton Fund, the Harvard Catalyst Clinical and Translational Research Center (NCATS grant no. 8UL 1TR000170; to M.K.O.), and the Boston Children's Hospital Pediatric Associates Award (to M.K.O.). |
|
Disclosure of potential conflict of interest: L. S. Miller has received grant support from MedImmune, Pfizer, Regeneron Pharmaceuticals, Moderna Therapeutics, and Boehringer Ingelheim; is on the scientific advisory board for Integrated Biotherapeutics; and is a shareholder of Noveome Biotherapeutics, which are all unrelated to the work reported in this article. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 143 - N° 4
P. 1426 - avril 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?